A股異動 | 百奧泰(688177.SH)大跌超17%創新低 終止BAT8001臨牀試驗
格隆匯2月9日丨百奧泰(688177.SH)大幅低開下挫,現大跌超17%,低見25.2元創上市以來新低價,成交額放大至9506萬元創階段新高,總市值105.6億元。百奧泰2月8日公吿,公司的BAT8001(即注射用重組人源化抗HER2單克隆抗體-美登素偶聯物)III期臨牀終點事件數達到方案規定可以進行統計分析的要求。根據公司的初步統計分析主要療效指標無進展生存期(PFS)相比對照組(拉帕替尼聯合卡培他濱)未達到預設的優效目標。經公司審慎考量BAT8001的後續開發風險,決定終止該項目的臨牀試驗。截至2020年12月,公司BAT8001研發項目累計投入2.26億元。按照相關會計準則和公司會計政策,該項目的全部研發支出已計入相應會計期間損益。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.